Zymeworks Announces Presentations for Ziihera® (zanidatamab-hrii) at 2026 AACR Annual Meeting

Core Insights - Zymeworks Inc. announced that its partner Jazz Pharmaceuticals will present four abstracts on zanidatamab at the AACR Annual Meeting, showcasing its potential across various HER2-expressing cancers [1][2][8] Group 1: Clinical Progress and Presentations - The presentations at AACR highlight the clinical progress of zanidatamab, demonstrating its efficacy beyond biliary tract cancer and gastroesophageal adenocarcinoma [2][3] - A Phase 2 trial (NeoZanHER) showed that zanidatamab significantly reduced tumor size in early-stage HER2+ breast cancer, with 30% of patients achieving pathologic complete response [5][4] - Additional studies will explore zanidatamab's utility in innovative biomarker-driven clinical trial designs [3][2] Group 2: Mechanism of Action and Development - Zanidatamab is a bispecific HER2-directed antibody that binds to two extracellular sites on HER2, leading to tumor growth inhibition through various mechanisms [7][8] - The FDA has granted multiple designations for zanidatamab, including Breakthrough Therapy and Fast Track designations for its development in specific cancer types [9][8] - Zymeworks is advancing a diverse pipeline of biotherapeutics, leveraging its proprietary technology to develop zanidatamab and other candidates [10][8]